Publicaciones en las que colabora con Javier Ampuero Herrojo (10)

2024

  1. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

    United European Gastroenterology Journal

  2. Novel insights into metabolic-associated steatotic liver disease preclinical models

    Liver International, Vol. 44, Núm. 3, pp. 644-662

2022

  1. Contribution of Liver and Pancreatic Islet Crosstalk to β-Cell Function/Dysfunction in the Presence of Fatty Liver

    Frontiers in Endocrinology, Vol. 13

  2. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

    Scientific Reports, Vol. 12, Núm. 1

  3. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

2021

  1. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases

    Frontiers in Immunology, Vol. 12

2019

  1. Co-03. La ldl oxidada es un biomarcador distintivo de la presencia de esteatohepatitis frente a fibrosis hepática en enfermedad hepática metabólica grasa

    Revista andaluza de patología digestiva, Vol. 42, Núm. 5, pp. 199-199

  2. Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models

    Revista Espanola de Enfermedades Digestivas, Vol. 111, Núm. 4, pp. 301-307

2018

  1. Co-21. Uso de microarns como biomarcadores no invasivos en enfermedad hepática metabólica por depósito de grasa no alcohólica

    Revista andaluza de patología digestiva, Vol. 41, Núm. 5, pp. 289-290

2017

  1. Co-12. Papel del factor de crecimiento de fibroblasto 21 (fgf21) en pacientes con eghna: Estudio genético y funcional.

    Revista andaluza de patología digestiva, Vol. 40, Núm. 5, pp. 277-277